Utilizing CD30 expression as a rational target for therapy of lymphoma by Kim, Won Seog
MEETING ABSTRACT Open Access
Utilizing CD30 expression as a rational target for
therapy of lymphoma
Won Seog Kim
From New development in Hematology and Oncology in 2011
Guangzhou, China. 25-26 December 2011
Introduction
Rituximab, identified through pivotal lymphoma
research, was the first monoclonal antibody approved by
the US FDA in 1997. Since the success of rituximab,
monoclonal antibodies have been a major focus for
development of targeted agents for lymphoma treat-
ment. A major hurdle in the development of a new anti-
body is finding a new target antigen. CD30 is an
attractive therapeutic target antigen, because it has been
identified as a marker of Reed–Sternberg cells in Hodg-
kin lymphoma (HL) [1], it is known to be expressed on
anaplastic large cell lymphoma (ALCL), some cases of
mediastinal large cell lymphoma, primary effusion lym-
phoma and multiple myeloma. However, its expression
on normal tissues is restricted to a small number of
activated B- and T-lymphocytes [2]. Thus, based on its
expression pattern, CD30 could be an ideal therapeutic
target.
Naked CD30 targeting antibodies and modified/
engineered anti-CD30 antibodies
Although CD30 is considered an ideal target, the results
from early clinical trials with first-generation naked
monoclonal antibodies targeting CD30 have been
disappointing.
Iratumumab (MDX-60) is a fully humanized anti-
CD30 monoclonal antibody. Of 72 patients with HL or
ALCL, clinical responses were observed in 6 (4 complete
response [CR] and 2 partial response [PR]) [3]. SGN-30
is a chimeric anti-CD30 monoclonal antibody. In a
phase I trial, one CR was reported in a patient with
cutaneous ALCL [4]. In a phase II trial for HL or ALCL,
7 responses (2 CR, 5 PR) in patients with ALCL were
reported in 79 patients. Unfortunately, there were no
responders in the 38 HL patients [5].
XmAb2513 is a modified anti-CD30 antibody with
increased binding affinity to the Fc receptor. In vitro
data showed more potent and efficacious cell killing
than first-generation anti-CD30 monoclonal antibodies
XDA-060 and SGN-30. In clinical trials, only phase I
data are available. Therefore, the data are insufficient to
assess whether the response is better than that with
unmodified antibodies [6].
Radioimmunoconjugation
Radiation itself is quite an efficient tool for killing lym-
phoma cells. If a good radiation source, a well-targeted
monoclonal antibody and a conjugation technique are
available, a radioimmunotherapeutic agent can be a good
option in lymphoma treatment. Already radioimmunocon-
jugations using diverse radionuclides (including
90Ya n d
131I) are being investigated. In a preclinical animal model,
the survival of mice was significantly prolonged by treat-
ment with anti-CD30 antibody HeFi-1 coupled to
90Y [7].
The novel anti-CD30 monoclonal antibody Ki-4 conju-
gated with
131I (total dose 0.0035–0.99 Gy) was trialed in
22 patients with refractory or relapsed HL. One CR, 5 PRs,
and 3 minor responses were achieved. However, 7 patients
experienced grade 4 hematologic toxicity 4 to 8 weeks
after treatment. Therefore, the development of this drug
did not continue [8].
Antibody–drug conjugate: brentuximab–vedotin
(SGN-35)
Brentuximab–vedotin (SGN-35) is an anti-CD30 mono-
clonal antibody conjugated to monomethyl auristatin E
(MMAE), a synthetic antitubulin agent. Through bind-
ing with CD30, brentuximab–vedotin is internalized.
Inside the lysosomes of lymphoma cells, free MMAE is
released. Therefore, no immune response is required to
achieve efficacy [9].
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every 3 weeks or weekly) have been conducted. In the
schedule with treatment every 3 weeks, the maximal tol-
erated dose was 1.8 mg/kg. Objective responses were
observed in 17 of 45 relapsed or refractory CD30-positive
hematologic malignancies including HL and ALCL. Of
the responders, 11 achieved CR [10]. In a phase II trial
with 102 patients with relapse after autologous stem cell
transplantation (ASCT), who were treated with 1.8 mg/
kg every 3 weeks, the overall response was around 75%
(32% CR) with a median duration of response of 6.7
months. In a single arm phase II trial including 58
relapsed systemic ALCL patients, the overall response
was 86% (58% CR), with a median duration of response
of 12.6 months.
Based on these excellent outcomes, brentuximab–vedo-
tin was approved by the FDA in August 2011. In HL
patients, brentuximab–vedotin is indicated after the failure
of ASCT or after the failure of at least two prior regimens
of combination chemotherapy if the patients are not
ASCT candidates. In systemic ALCL patients, it is
approved after failure of at least one prior multiagent
chemotherapy.
Overcoming the limitations of anti-CD30
targeting antibodies
Based on its expression patterns, CD30 should be a good
therapeutic target. However, it can be shed in a soluble
form, resulting in a reduction in the effect of anti-CD30
monoclonal antibodies by competitive binding. Thus,
developing a monoclonal antibody targeting membrane-
associated CD30 epitopes (Ep2: amino acids 107–153, Ep7
amino acids 282–338) may have potential advantages [11].
Although antibodies have exquisite selectivity for tumor
over normal tissue, antibody localization to tumors is inef-
ficient. Diabodies (50–55 kDa) can penetrate tumor more
rapidly and accumulate more drug in tumors because they
are smaller than IgG (150 kDa). An anti-CD30 diabody–
drug conjugate (diabody-vcF4) showed potent antitumor
activity and tolerable toxicity in a mouse model [12].
Future directions
After the early success of anti-CD30 monoclonal antibo-
dies, a variety of clinical trials are ongoing. These anti-
bodies can be combined as a part of first-line treatment,
for example, combining ABVD with different levels of
SGN-35, as part of salvage combination chemotherapy,
maintenance, or as part of a conditioning regimen. After
more information is obtained through clinical trials in
the near future, new therapeutic strategies can be
defined.
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